Skip to main content
. Author manuscript; available in PMC: 2010 Oct 20.
Published in final edited form as: HIV Clin Trials. 2010 Jan–Feb;11(1):51–58. doi: 10.1310/hct1101-51

Figure 2.

Figure 2

Effect of vicriviroc (VCV vs. placebo) on various neuropathic outcomes (odds ratios [OR] and 95% CIs), adjusted for baseline status of neuropathic outcomes and baseline neurotoxic nucleoside reverse transcriptase inhibitor(s) (RTI) use. PN = peripheral neuropathy; PPN = painful neuropathy; SPN = symptomatic neuropathy.